Global perinatal infections market is gaining traction because of the increasing cases of HIV and incidences of perinatal infections.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, expects the global perinatal infections market size to grow at a steady CAGR of 7.3% during the forecast period between 2023 and 2029. High birth rates and an increasing yearly birth rate, as well as unsanitary circumstances around expectant mothers, particularly in developing countries, are major growth drivers for the global perinatal infections market. During the period in analysis, it is forecast that perinatal infections would continue to rise in prevalence due to the rising rate of preterm births.
Global Perinatal Infections Market – Overview
Perinatal infections are infections that can be passed from the person giving birth to the newborn during pregnancy, childbirth, or the first few hours following birth. Because newborns, especially those born preterm, have a limited capacity for symptom expression, even little variations from the norm should be taken as a sign of bacterial illness. Infections like the flu, vaginal yeast infections, dermatitis, herpes, uterine infections, group B streptococcus (GBS), bacterial vaginosis (BV), and listeria are frequently seen during pregnancy.
Global Perinatal Infections Market – By End User
Based on end user, the global Perinatal Infections market is segmented into hospitals, homecare, specialty clinics, and others. The hospital segment accounts for the highest market share, as hospitals are considered the safest settings for delivery. According to the National Academics, a vast majority of Americans, around 98.4%, give birth in a hospital, which contributes to the segment’s growth. However, homecare and specialty clinics are also projected to register a high growth rate during the forecast period owing to the growing number of pregnant people opting to give birth outside of hospitals, either at home or in specialized birthing facilities known as birth centers.
Impact of COVID-19 on Global Perinatal Infections Market
According to research published in the National Center for Biotechnology Information, no specific or convincing evidence exists to support the notion that SARS-CoV and MERS-CoV are vertically transmitted. Similarly, there is not enough evidence at this time to demonstrate that COVID-19 is transmitted vertically. However, a newborn delivered to a pregnant person who had COVID-19 was said to have higher IgM antibody levels to SARS-CoV-2 in blood two hours after delivery, indicating that COVID-19 may have the potential for vertical transmission. This resulted in significant growth in the overall global perinatal infections market.
Major players operating in the global perinatal infections market include Merck KGaA, Beckman Coulter Inc., BIOMERIEUX, Bio-Rad Laboratories, Inc, Danaher, Hologic Inc., Gilead Sciences, Inc., Emcure Pharmaceuticals Limited., Cipla Inc., Hetero, Bausch Health Companies Inc., Johnson & Johnson Private Limited, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Novartis AG, and Sun Pharmaceutical Industries Ltd.
To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and the Global Perinatal Infections Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Perinatal Infections Marketand industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
BlueWeave Research Blog
Phone No: +1 866 658 6826